Bristol-Myers, 3M and Deckers rise premarket; Dexcom falls
) stock rose 6.5% after the industrial conglomerate raised the low end of its full-year adjusted profit forecast expecting to benefit from restructuring measures and increasing demand for electronics.) stock rose 4.6% after the drugmaker posted better-than-expected second-quarter results, driven by growth from new products like anemia treatment Reblozyl and heart drug Camzyos as well as from its top-seller, blood thinner Eliquis.) stock rose 1.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Stocks making the biggest moves after hours: Dexcom, Coursera, Deckers Outdoor and moreThese are the stocks posting the largest moves in extended trading.
Read more »
Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costsThe results come as Bristol Myers moves to cut $1.5 billion in costs by 2025 and reinvest that money into key drug brands and research and development programs.
Read more »
Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs The results come as Bristol Myers moves to cut $1.5 billion in costs by 2025 and reinvest that money into key drug brands and research and development programs.
Read more »
Bristol Myers to pay $2.7 million to settle Israel anti-competition chargesBristol Myers to pay $2.7 million to settle Israel anti-competition charges
Read more »
Dexcom cuts guidance as Q2 revenue falls short of estimates; shares slumpDexcom cuts guidance as Q2 revenue falls short of estimates; shares slump
Read more »
Dexcom shares plummet more than 30% after company lowers fiscal year guidanceDexcom shares plunged on disappointing revenue and weak guidance. The stock was down 13% for the year as of Thursday’s close. Dexcom makes continuous…
Read more »